KZA — Kazia Therapeutics Income Statement
0.000.00%
Last trade - 00:00
HealthcareSpeculativeMicro Cap
- AU$18.24m
- AU$14.80m
- AU$0.02m
2019 June 30th | 2020 June 30th | 2021 June 30th | R2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.1 | 0.066 | 15.2 | 0.002 | 0.023 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8.88 | 12.7 | 24.1 | 25.4 | 20.8 |
Operating Profit | -8.78 | -12.6 | -8.91 | -25.4 | -20.7 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10.6 | -12.8 | -8.91 | -25.4 | -20.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10.3 | -12.5 | -8.42 | -25 | -20.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -10.3 | -12.5 | -8.42 | -25 | -20.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10.3 | -12.5 | -8.42 | -25 | -20.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.17 | -0.16 | -0.057 | -0.189 | -0.123 |